ERBB2 and breast carcinoma: In HER2-positive breast cancer, trastuzumab and pertuzumab are often coadministered because of their synergistic mechanisms of action and routinely given in the neoadjuvant setting in combination with cytotoxic chemotherapy with the goal of achieving complete pathologic response.